Mechanisms of phosphorus and calcium homeostatic disorders in the development of cardiovascular events in patients with chronic renal diseases. The role of fibroblast growth factor 23 and Klotho

Terapevticheskii Arkhiv

Volumn 82, Issue 6, 2010, Pages 66-72

  Milovanova, L Yu ^a   Kozlovskaya, L V ^a   Milovanov, Yu S ^a   Bobkova, I N ^a   Dobrosmyslov, I A ^a  

^a I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Calcification; Chronic heart disease; Hyperphosphatemia; Morphogenetic proteins

Indexed keywords

BETA GLUCURONIDASE; CALCIUM; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 23; KLOTHO PROTEIN; PHOSPHORUS;

BIOSYNTHESIS; BLOOD; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; HOMEOSTASIS; HUMAN; KIDNEY DISEASE; METABOLISM; REVIEW;

CALCIUM; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; FIBROBLAST GROWTH FACTORS; GLUCURONIDASE; HOMEOSTASIS; HUMANS; KIDNEY DISEASES; PHOSPHORUS;

EID: 77955584874     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Zhang Qiu-Li, Rothenbacher D. Prevalence of chronic kidney disease in population-based studies: Systematic review. BMC Publ. Hlth 2008; 8: 117.
2. Coresh J., Selvin E., Stevens L. A. et al. Prevalence of chronic kidney disease in the United States. J. A. M. A. 2007; 298: 2038-2047. (Pubitemid 350074801)
3. Hruska K. A., Mathew S., Lund R. et al. Author manuscript; available in PMC 2009. Hyperphosphatemia of chronic kidney disease. Kidney Int. 2008; 74 (2): 148-157.
4. Foley R. N., Parfrey P. S., Sarnak M. J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am. J. Kidney Dis. 1998; 32: S112-S119.
5. London G. M. Cardiovascular risk in end-stage renal disease: vascular aspects. Nephrol. Dial. Transplant. 2000; 15 (suppl. 5): 97-104.
6. Go A. S., Chertow G. M., Fan D. et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 2004; 351: 1296-1305.
7. Sarnak M. J., Levey A. S., Schoolwerth A. C. et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003; 42: 1050-1065.
8. Wright J., Hutchison A. Cardiovascular disease in patients with chronic kidney disease. Vasc. Hlth Risk Manag. 2009; 5: 713-722.
9. Locatelli F., Marcelli D. et al. Cardiovascular disease in chronic renal failure: the challenge continues. Nephrol. Dial. Transplant. 2000; 15 (suppl. 5): 69-80.
10. Parfey P. S. Cardiac disease in dialysis patients: diagnosis, burden of disease, prognosis, risk factors and management. Nephrol. Dial. Transplant. 2001; 15 (suppl. 5): 58-68.
11. Levin A. Clinical epidemiology of cardiovascular disease in chronic kidney disease prior to dialysis. Semin. Dial. 2003; 16 (2): 101-105. (Pubitemid 37361072)
12. Gutiérrez O. M. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009; 119: 2545-2552.
13. Block G. A., Hulbert-Shearon T. E., Levin N. W. et al. Association of serum phosphorus and calcium X phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am. J. Kidney Dis. 1998; 31: 607-617.
14. Kestenbaum B., Sampson J. N., Rudser K. D. et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J. Am. Soc. Nephrol. 2005; 16: 520-528.
15. Westerberg P. A. et al. Regulation FGF-23 in CKD. Nephrol. Dial. Transplant. 2007; 22 (11): 3202-3207.
16. Nakanishi S. et al. Serum FGF-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int. 2005; 68(1): 410-411.
17. Yean G. et al. High levels of serum FGF-23 are associated with increased mortality in long haemodialysis patients. Nephrol. Dial. Transplant. 2009; 24 (9): 2792-2796.
18. Gutiérrez O. M., Mannstadt M., Isakova T. et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N. Engl. J. Med. 2008; 359: 584-592.
19. Makoto K. Klotho in chronic kidney disease. What's new? Nephrol. Dial. Transplant. 2009; 24 (6): 1705-1708.
20. Ramon I. et al. FGF-23 and its role in phosphate homeostasis. Eur. J. Endocrinol. 2010; 162(1): 1-10.
21. Shigematsu T. et al. Possible involvement of circulating FGF-23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am. J. Kidney Dis. 2004; 44 (2): 250-256.
22. Razzaque M. S. Does FGF-23 toxicity influence the outcome of chronic kidney disease? Nephrol. Dial. Transplant. 2009; 24 (1): 4-7.
23. Marchais S. J., Metivier F., Guerin A. P. et al. Association of hyperphosphataemia with haemodynamic disturbances in end-stage renal disease. Nephrol. Dial. Transplant. 1999; 14: 2178-2183.
24. Craver L., Marco M. P., Martinez I. et al. Mineral metabolism parameters throughout chronic kidney disease stages 1-5 - achievement of K/DOQI target ranges. Nephrol. Dial. Transplant. 2007; 22: 1171-1176.
25. Davies M. R., Lund R. J., Mathew S. et al. Low turnover osteodystrophy and vascular calcification are amenable to skeletal anabolism in an animal model of chronic kidney disease and the metabolic syndrome. J. Am. Soc. Nephrol. 2005; 16: 917-928.
26. Jono S., McKee M. D., Murry C. E. Phosphate regulation of vascular smooth muscle cell calcification. Circ. Res. 2000; 87: 10-17.
27. Guillaume J. Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences. Nephrol. Dial. Transplant. 2009; 24 (3): 948-955.
28. Raggi P., Boulay A., Chasan-Taber S. et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J. Am. Coll. Cardiol. 2002; 39: 695-701.
29. London G. M., Guerin A. P., Marchais S. J. et al. Arterial media calcification in end-stage renal diseases: impact on allcause and cardiovascular mortality. Nephrol. Dial. Transplant. 2003; 18: 1731-1740.
30. Isakova T., Gutierrez O. et al. Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD. J. Am. Soc. Nephrol. 2008; 19 (3): 615-623.